Of the 1117 patients included, 420 (38%) had KRAS mut tumours, 142 (13%) had EGFR mut tumours, 12 (1%) had ALK rearranged tumours, and 3 (0.3%) patients had ROS1 rearranged tumours. This evidence concerns the gene EGFR and neoplasm.